Results 71 to 80 of about 37,681 (214)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin

Patient Related Outcome Measures, 2011
Bob Djavan, Seyed Saeid Dianat, Amir KazzaziNew York University, Department of Urology, New York, USABackground: Benign prostatic hyperplasia, the fourth most commonly diagnosed medical condition in the elderly, is a major underlying cause of lower ...
Djavan B, Dianat SS, Kazzazi A
doaj  

Pterostilbene Effect on Inflammatory and Oxidation Markers in Benign Prostatic Hyperplasia Rats Model

Iraqi Journal of Pharmaceutical Sciences
Pterostilbene is a potent anti-inflammatory and antioxidant used to treat benign prostatic hyperplasia, which is brought on by the induction of testosterone propionate.
Mohammed Ridha Jawad, Ghaith Ali Jasim
doaj   +1 more source

Assessing the Influence of Sexual Activity on Benign Prostatic Hyperplasia [PDF]

International Journal of Medical Arts
Background: Benign prostatic hyperplasia [BPH] is a frequent cause of lower urinary tract symptoms [LUTS] in men and is a common histological finding, particularly in aging men.
Muhammed Elgendy, Ahmed Salem, Ahmad Abdel-Hameed, Amr Hussein   +3 more
doaj   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

Prostate blood flow in patients with benign prostatic hyperplasia complicated by urine retention

RUDN Journal of Medicine, 2012
Benign prostatic hyperplasia is the most frequent disease among middle and old aged men and connected with increasing of lifetime of men. The incidence of the disease is 42% to 87% in different aged groups.
E A Atamanova, V P Avdoshin, M I Andryukhin, V V Chugaev   +3 more
doaj  

Magnitude and factors associated with benign prostatic hyperplasia among adult male patients visiting Wolaita Sodo University comprehensive specialized hospital southern Ethiopia

Scientific Reports
Worldwide, in Africa and Ethiopia prevalence of Benign Prostatic Hyperplasia among patients with lower urinary tract symptoms was 26.2%, 44.2%, and 33.4% respectively.
Tirufat Tiruneh, Tamiru Getachew, Firdawek Getahun, Tesfaye Gebreyesus, Simeon Meskele   +4 more
doaj   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Antioxidant capacity of Chuquiraga spinosa Less and Senecio rhizomatus Rusby and their effects on the progression of testosterone enanthate-induced prostatic hyperplasia in rats [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Benign prostatic hyperplasia affects men older than 50 years and can progress to atypical prostatic hyperplasia. Conventional pharmacotherapy causes adverse effects, affecting adherence and leading to the use of phytotherapy as a complementary ...
Hugo Jesús Justil-Guerrero, Jorge Luis Arroyo-Acevedo, Juan Pedro Rojas-Armas, Carlos Javier Justil-Guerrero, María Cecilia Rondón-Ramos, Jessica Yolanda Huarcaya-Rojas   +5 more
doaj   +1 more source

Treatment of benign prostate hyperplasia [PDF]

Orvosi Hetilap, 2010
A koztudatban az urologiahoz kotődő leggyakoribb betegseg a vizeleturites zavara, amelyet kulonboző betegsegek okoznak, es amelynek osszefoglalo elnevezese a LUTS (lower urinary tract symptoms). A vizeleturitesi zavarok leggyakoribb oka a benignus prostatahyperplasia (BPH), bar a BPH-nak standardizalt klinikai defi nicioja nincs.
openaire   +2 more sources

Mapping the lineage of prostate tissue ablation medical device predicates for focal therapy of prostate cancer approved via the FDA 510(k) clearance pathway

Surgical Practice, EarlyView.
Abstract Objective Medical devices are reviewed by the US Food and Drug Administration (FDA) for safety and effectiveness. Class II devices can receive 510(k) clearance if they are “substantially equivalent” to an existing predicate device. This process can be repeated iteratively, leading to a lineage of predicates for newly cleared devices.
Yiting Lin, Amir Khan, Arvin George, Mohummad Minhaj Siddiqui   +3 more
wiley   +1 more source